Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Research

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1538-7445.SABCS14-S3-01
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Case report: An exceptional responder of low-dose continuous 5-FU in a patient with de-novo stage IV triple-negative breast cancer with liver and bone marrow failure

  2024cites this paper
• Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency

  2023cites this paper
• Biomarkers of Homologous Recombination Deficiency in the era of PARP inhibitors

  2022cites this paper
• The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers

  2021cites this paper
• Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma

  2021cites this paper
• Pharmacoeconomic analysis of atezolizumab plus nab-paclitaxel in the treatment of the advanced or metastatic triple-negative breast cancer

  2020cites this paper
• Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

  2020cites this paper
• Diagnostic value of Doppler ultrasound parameters combined with MMP-11 in early breast cancer and benign breast diseases

  2020cites this paper
• Olaparib in the metastatic HER2-negative breast cancer setting

  2020cites this paper
• Establishing a Program for Young Women at High Risk for Breast Cancer

  2020cites this paper
• Management of Advanced Breast Cancer in Young Women: What’s New in Systemic Treatment

  2020cites this paper
• Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer

  2019cites this paper
• Homologous recombination deficiency in triple negative breast cancer.

  2019cites this paper
• Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

  2019cites this paper
• Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy?

  2019cites this paper
• Triple-Negative Breast Cancer

  2019cites this paper
• Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

  2019cites this paper
• 1-21-2019 CCNE 1 amplification is associated with poor prognosis in patients with triple negative breast cancer

  2019cites this paper
• CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer

  2019cites this paper
• Therapeutic implications of germline genetic findings in cancer

  2019cites this paper
• Cisplatin shows greater efficacy than gemcitabine when combined with nab-paclitaxel in metastatic triple-negative breast cancer

  2019cites this paper
• Innovations and Challenges in the Treatment of Metastatic Triple-Negative Breast Cancer.

  2018cites this paper
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  2018cites this paper
• Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review

  2018cites this paper
• Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer

  2018cites this paper
• Triple-Negative Breast Cancer: Expression of Hypoxia-Inducible Factor 1α in Triple-Negative Breast Cancer with Metastasis to Lymph Nodes

  2018cites this paper
• Isolated thoracic perfusion in lung metastases from breast cancer: a retrospective observational study

  2018cites this paper
• Outcomes of systemic therapy for advanced triple-negative breast cancer: A single centre experience.

  2018cites this paper
• Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy

  2018cites this paper
• Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

  2018cites this paper
• Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives

  2018cites this paper
• Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort

  2018cites this paper
• Genetic Markers in Triple‐Negative Breast Cancer

  2018cites this paper
• Male BRCA mutation carriers: clinical characteristics and cancer spectrum

  2018cites this paper
• The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

  2018cites this paper
• Therapeutic landscape in mutational triple negative breast cancer

  2018cites this paper
• Development of Breast Cancer Choices: a decision support tool for young women with breast cancer deciding whether to have genetic testing for BRCA1/2 mutations

  2018cites this paper
• Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer

  2018cites this paper
• Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?

  2018cites this paper
• nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

  2018cites this paper
• BRCA1/2 testing: therapeutic implications for breast cancer management

  2018cites this paper
• Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results

  2018cites this paper
• Biomarkers for Homologous Recombination Deficiency in Cancer

  2018cites this paper
• Whole-Genome Sequencing in Cancer.

  2018cites this paper
• Neoadjuvant Treatment of Stage IIB/III Triple Negative Breast Cancer with Cyclophosphamide, Doxorubicin, and Cisplatin (CAP Regimen): A Single Arm, Single Center Phase II Study (GBECAM 2008/02)

  2018cites this paper
• Multi-gene Panel Testing in Breast Cancer Management.

  2018cites this paper
• Triple negative breast cancer in Asia: An insider's view.

  2018cites this paper
• Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies

  2018cites this paper
• Olaparib for the treatment of breast cancer

  2018influential citation
• An update on first line therapies for metastatic breast cancer

  2018cites this paper
• Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors

  2018cites this paper
• Genetic variation in the DNA repair pathway as a potential determinant of response to platinum‐based chemotherapy in breast cancer

  2018cites this paper
• Chemotherapy and HER2-Directed Therapy for Metastatic Breast Cancer

  2018cites this paper
• Primary Systemic Therapy for Breast Cancer

  2018cites this paper
• Metastatic Breast Cancer: Prognosis, Diagnosis and Oncological Management

  2018cites this paper
• Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer

  2018cites this paper
• De-escalating and escalating systemic therapy in triple negative breast cancer.

  2017cites this paper
• Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy

  2017cites this paper
• The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting

  2017cites this paper
• The fate of BRCA1-related germline mutations in triple-negative breast tumors.

  2017cites this paper
• Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

  2017cites this paper
• Germline Mutations in Triple-Negative Breast Cancer

  2017cites this paper
• De-escalating and escalating systemic therapy of early breast cancer.

  2017cites this paper
• Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field.

  2017cites this paper
• Identification of recurrent BRCA1 mutation and its clinical relevance in Chinese Triple‐negative breast cancer cohort

  2017cites this paper
• Practical Approach to Triple-Negative Breast Cancer.

  2017cites this paper
• Prostate cancer: Developing novel approaches to castration‐sensitive disease

  2017influential citation
• Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

  2017cites this paper
• Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer

  2017cites this paper
• Molecular alterations in triple-negative breast cancer-the road to new treatment strategies.

  2017cites this paper
• A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

  2017cites this paper
• B-CAN: a resource sharing platform to improve the operation, visualization and integrated analysis of TCGA breast cancer data

  2017cites this paper
• BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.

  2017cites this paper
• SABCS 2016: systemic therapy for metastatic breast cancer

  2017cites this paper
• 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

  2017cites this paper
• Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?

  2017cites this paper
• ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3).

  2017cites this paper
• Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First‐Line Treatment of Metastatic Triple‐Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group

  2017cites this paper
• Intensiviertes Früherkennungsprogramm - Risikoadaptierte Betreuungskonzepte bei Mammakarzinom-Hochrisikopatientinnen

  2017cites this paper
• Analysis of BRCA1 /2 Mutations and Performance of Manchester Scoring System in High Risk Iranian Breast Cancer Patients: A Pilot Study

  2017cites this paper
• Risikoadaptierte Betreuungskonzepte bei Mammakarzinom-Hochrisikopatientinnen

  2017cites this paper
• Chemotherapy Regimens in the Adjuvant and Advanced Disease Settings

  2017cites this paper
• Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?

  2017cites this paper
• Medical Management of Breast Cancer in BRCA Mutation Carriers

  2017cites this paper
• Treatment of Advanced Disease: Guidelines

  2017cites this paper
• Exploiting Homologous Recombination Deficiency in TNBC

  2017cites this paper
• Exploring the role of Interleukin-6 and other host-associated factors in tumor progression and metastasis development

  2017cites this paper
• Can advanced-stage ovarian cancer be cured?

  2016cites this paper
• Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

  2016cites this paper
• PERORAL FORMS OF CYTOSTATIC DRUGS IN THERAPY OF METASTATIC MAMMARY GLAND CANCER:

  2016cites this paper
• Neoadjuvant, anthracycline-free chemotherapy with carboplatin and docetaxel in triple-negative, early-stage breast cancer: a multicentric analysis of rates of pathologic complete response and survival

  2016cites this paper
• Cancer susceptibility genes and their potential implication regarding systemic therapy for early‐stage breast cancer

  2016cites this paper
• BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.

  2016cites this paper
• Genetics of triple-negative breast cancer: Implications for patient care.

  2016cites this paper
• Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice

  2016cites this paper
• Novel Treatments in Breast Cancer

  2016cites this paper
• A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial

  2016cites this paper
• Treatment of breast cancer: dealing with toxicity

  2016influential citation
• Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression

  2016cites this paper
• Molecular Classification of Triple-Negative Breast Cancer

  2016cites this paper